These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Profound hypotension following a "test dose" of bretylium tosylate. Alfery DD; Denlinger JK Anesth Analg; 1979; 58(6):516-8. PubMed ID: 574738 [No Abstract] [Full Text] [Related]
43. [Action of ornid and papavperine on the biopotential and electrolytic balance of the vascular wall]. Gul'kin AV; Kuzin VP Farmakol Toksikol; 1975; 38(5):579-82. PubMed ID: 1183589 [TBL] [Abstract][Full Text] [Related]
44. The influence of bretylium tosylate on the intraocular pressure of the rabbit. Krieglstein GK Albrecht Von Graefes Arch Klin Exp Ophthalmol; 1975 Nov; 197(2):153-8. PubMed ID: 1082263 [TBL] [Abstract][Full Text] [Related]
46. Paradoxical ventricular tachycardia and fibrillation after intravenous bretylium therapy. Report of two cases. Anderson JL; Popat KD; Pitt B Arch Intern Med; 1981 May; 141(6):801-2. PubMed ID: 7235792 [TBL] [Abstract][Full Text] [Related]
47. [Neurochemical mechanisms of artifical hypobiosis and chemical thermoregulation]. Timofeev NN; Konstantinov GA Fiziol Zh SSSR Im I M Sechenova; 1985 Sep; 71(9):1145-50. PubMed ID: 4054399 [TBL] [Abstract][Full Text] [Related]
48. Muscarinic receptor heterogeneity revealed by interaction with bretylium tosylate. Different ligand-receptor conformations versus different receptor subclasses. Schreiber G; Sokolovsky M Mol Pharmacol; 1985 Jan; 27(1):27-31. PubMed ID: 3965929 [TBL] [Abstract][Full Text] [Related]
52. [Particular features of the impact of certain vegetotropic drugs on the excitability of cholinergic structures, contractile myocardial function and electromotive stomach activity]. Lychkova AE Eksp Klin Gastroenterol; 2005; (5):79-81, 124-5. PubMed ID: 16518920 [TBL] [Abstract][Full Text] [Related]
53. Stability and visual compatibility of bretylium tosylate with selected large-volume parenterals and additives. Perentesis GP; Piltz GW; Kirshcenbaum HL; Navalakha P; Aronoff W; Cutie AJ Am J Hosp Pharm; 1983 Jun; 40(6):1010-2. PubMed ID: 6869385 [TBL] [Abstract][Full Text] [Related]
54. [Effect of ornid on protein biosynthesis in the liver during its experimental neurogenic dystrophy]. Korkhov VV Farmakol Toksikol; 1971; 34(4):435-8. PubMed ID: 5160786 [No Abstract] [Full Text] [Related]
55. Bretylium tosylate intravenous admixture compatibility. II: Dopamine, lidocaine, procainamide, and nitroglycerin. Lee YC; Malick AW; Amann AH; Baaske DM; Shah JJ; Wagenknecht DM; Carter JE Am J Hosp Pharm; 1981 Feb; 38(2):183-7. PubMed ID: 6782870 [No Abstract] [Full Text] [Related]
56. Cardiovascular therapeutics--overview of a symposium. Heart Lung; 1980; 9(2):263-88. PubMed ID: 6898603 [No Abstract] [Full Text] [Related]
57. [The effect of Ornid on intraocular pressure of patients with glaucoma]. Tregubova RS Oftalmol Zh; 1967; 22(4):261-4. PubMed ID: 5613111 [No Abstract] [Full Text] [Related]
58. [Clinical experience with the anti-arrhythmic activity of bretylium tosylate]. Calabrese P; Rizzon P Boll Soc Ital Cardiol; 1972; 17(7):407-12. PubMed ID: 4650835 [No Abstract] [Full Text] [Related]
59. Effects of bretylium tosylate on voltage-gated potassium channels in human T lymphocytes. Gáspár R; Panyi G; Ypey DL; Krasznai Z; Vereb G; Pieri C; Damjanovich S Mol Pharmacol; 1994 Oct; 46(4):762-6. PubMed ID: 7969057 [TBL] [Abstract][Full Text] [Related]